All
Adcetris Combination Granted Priority Review for Hodgkin Lymphoma Treatment
January 3rd 2018Adcetris (brentuximab vedotin) was granted a priority review to a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) to be used in combination with Adriamycin, vinblastine and dacarbazine (AVD) to treat patients with classical Hodgkin lymphoma in the frontline setting, according to Seattle Genetics, the company developing the drug.
Wishing Cancer Survivors a New Year With Fewer Fears
January 2nd 2018Some cancer survivors are good at getting on with life. Some of us remain timid about the prospect of life, even when a prognosis is good. A new year is a good time to try harder to seize the day, whatever the future is likely to bring.
FDA Grants Priority Review for Rare Neuroendocrine Tumor Treatment
January 2nd 2018The Food and Drug Administration (FDA) granted a priority review designation to a novel version of Azedra (iobenguane I-131), a radiopharmaceutical, to treat patients with malignant or recurrent pheochromocytoma or paraganglioma (PPGL).
Thyroid Cancer Survivors Diagnosed Before 40 At Higher Risk For Aging-Related Disease
December 31st 2017Patients diagnosed with thyroid cancer before the age of 40 appear to be at the highest risk for age-related diseases, including heart disease and diabetes, compared with their age-matched counterparts.
Facing the Responsibilities of the New Year
December 29th 2017The new year impacts breast cancer survivors in a vastly different ways than it does most people. Our resolutions, especially health-related resolutions, can be detrimental to our health if we don't keep them. This survivor shares her own chagrin at failing to keep some promises.
3-D Simulation Helps Patients See Radiation Therapy Plan Firsthand
December 29th 2017The Virtual Environment Radiotherapy Training (VERT™) system, originally designed to teach medical students and physicians about administering radiation therapy, is being used to explain to people who have prostate cancer what their treatment will look like.
Foundation Continues Legacy to 'Never Give Up'
December 29th 2017The V Foundation for Cancer Research was founded by ESPN and legendary basketball coach Jim Valvano with one goal in mind: to achieve victory over cancer. Since its start in 1993, the V Foundation has awarded over $200 million in cancer research grants nationwide and has grown to become one of the premier supporters of cutting-edge cancer research funds.
Foundation for Women's Cancer Fights to End Clinical Trial Crisis
December 29th 2017In recent years, the number of available gynecologic cancer clinical trials has gone down. The Foundation for Women's Cancer educates women about the trials that are available, and encourages them speak up publicly about the need for more.
CURE Media Group Partners with the Lung Cancer Foundation of America
December 28th 2017CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, has expanded its Strategic Alliance Partnership (SAP) Program by uniting with the Lung Cancer Foundation of America (LCFA).